Exhibit 5.1
| | | | |
| | 53rd at Third |
| | 885 Third Avenue |
| | New York, New York 10022-4834 |
| | Tel: +1.212.906.1200 Fax: +1.212.751.4864 |
| | www.lw.com |
| FIRM / AFFILIATE OFFICES |
| Beijing | | Moscow |
| Boston | | Munich |
| | Brussels | | New York |
| | Century City | | Orange County |
July 30, 2019 | | Chicago | | Paris |
| | Dubai | | Riyadh |
| | Düsseldorf | | San Diego |
| | Frankfurt | | San Francisco |
| | Hamburg | | Seoul |
| | Hong Kong | | Shanghai |
| | Houston | | Silicon Valley |
| | London | | Singapore |
| | Los Angeles | | Tokyo |
T2 Biosystems, Inc. 101 Hartwell Ave. Lexington, MA 02421 | | Madrid | | Washington, D.C. |
| Milan | | |
| File No. 057345-0001 |
| Re: | Registration Statement No. 333-227847; Shares of Common Stock, par value $.001 per share, having an aggregate offering price of up to $30,000,000. |
Ladies and Gentlemen:
We have acted as special counsel to T2 Biosystems, Inc., a Delaware corporation (the “Company”), in connection with the proposed issuance of shares of common stock, par value $0.001 per share (the “Common Stock”), with an aggregate offering price of up to $30,000,000 (the “Shares”). The Shares are included in a registration statement on FormS-3 under the Securities Act of 1933, as amended (the “Act”), initially filed with the Securities and Exchange Commission (the “Commission”) on October 15, 2018 (RegistrationNo. 333-227847) (as amended, the “Registration Statement”), and are being offered pursuant to a base prospectus dated October 24, 2018 (the “Base Prospectus”) and a prospectus supplement dated July 30, 2019 filed with the Commission on July 30, 2019 pursuant to Rule 424(b) under the Act (the “Prospectus Supplement,” and together with the Base Prospectus, the “Prospectus”). The Shares are being sold pursuant to an Equity Distribution Agreement dated July 30, 2019 by and between Canaccord Genuity LLC and the Company (the “Sales Agreement”).
This opinion is being furnished in connection with the requirements of Item 601(b)(5) of RegulationS-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related Prospectus, other than as expressly stated herein with respect to the issue of the Shares.
As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the “DGCL”), and we express no opinion with respect to any other laws.